Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
28 Juin 2023 - 3:00PM
NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of
two large studies that support the clinical utility of DPNCheck
screening in people with diabetes.
Ke and colleagues developed and validated an
algorithm to predict progression from mild non-proliferative
diabetic retinopathy (DR) to vision-threatening DR in type 2
diabetes. The model was created by analyzing 440 patients with
non-proliferative DR or vision-threatening DR. It was then
prospectively validated in 120 patients with mild non-proliferative
DR who were followed for a median of 42 months. The study
identified kidney function, insulin production and DPNCheck
abnormalities as the three independent predictors of progression to
vision-threatening DR. Common diabetes assessments including age,
disease duration, HbA1c, LDL, HDL and peripheral arterial disease
were not predictive.
Fukuda and colleagues evaluated 323 patients
with type 2 diabetes using a cross sectional design. Patients with
DPNCheck determined diabetic peripheral neuropathy had
significantly worse kidney function than those without, while there
was no difference between patients with and without diabetic
peripheral neuropathy according to traditional clinical criteria.
The authors further analyzed the data and found that DPNCheck
results were an independent predictor of kidney function despite
adjusting for multiple clinical variables.
"People with diabetes and a positive DPNCheck
test have a high probability of having peripheral neuropathy with
its attendant complications that include foot ulcers and increased
risk of falls. The two recently published studies demonstrate that
these individuals are at further risk for kidney and advanced eye
disease. These results emphasize the importance of accurately
identifying peripheral neuropathy at an early stage when all three
microvascular complications of diabetes are most responsive to
therapeutic interventions," said Shai N. Gozani, M.D., Ph.D., CEO
of NeuroMetrix. "It is also evident that traditional clinical
screening for peripheral neuropathy is poorly correlated to the
underlying pathophysiology of diabetes, which calls into question
its utility for identifying high-risk patients."
About Diabetic Peripheral
Neuropathy
Diabetic peripheral neuropathy (DPN) is the most
common long-term complication of diabetes, affecting half of people
with diabetes. The clinical and economic burden of DPN stems from
its central role in the development of foot ulcers that can lead to
lower extremity amputation. DPN also causes debilitating chronic
nerve pain and altered proprioception that increases the risk of
falling, particularly in the elderly. Overall, DPN is associated
with a substantial reduction in quality of life and decreased
activities of daily living.
About DPNCheck
DPNCheck is an automated, fast, accurate, and
quantitative sural nerve conduction test used to evaluate
peripheral neuropathies. It is designed to be used by clinicians at
the point-of-care to detect peripheral neuropathies at an early
stage when intervention is likely to be most effective, to stage
the severity of nerve deterioration and to monitor disease
progression and treatment benefits. For more information, visit
dpncheck.com.
About NeuroMetrix
NeuroMetrix is an innovation-driven company with
a mission to improve individual and population health through novel
medical devices and technology solutions for neurological disorders
and pain syndromes. The Company has three commercial products.
Quell® is a prescription wearable neuromodulator that is the only
FDA-authorized medical device to help reduce the symptoms of
fibromyalgia. DPNCheck® is a diagnostic device that provides rapid,
point-of-care detection of peripheral neuropathies. ADVANCE® is a
legacy diagnostic device that provides automated, in-office nerve
conduction studies for the evaluation of focal neuropathies. For
more information, visit www.neurometrix.com.
Source: NeuroMetrix, Inc.
Thomas T. HigginsSVP and Chief Financial
Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
NeuroMetrix (NASDAQ:NURO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024